Comparison of long-term overall survival with extrapolated overall survival for pembrolizumab assessed by Australian reimbursement authorities
{{output}}
Background: Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data. This study compared the accuracy of these ... ...
